Showing posts with label guidance. Show all posts
Showing posts with label guidance. Show all posts

Thursday, February 27, 2014

Mylan Surges on 2014 Guidance

Mylan (MYL) reported decent Q4 results and strong guidance for 2014 and beyond this morning. For details see my notes on the Mylan Q4 2014 analyst conference call.

Mylan sees a relatively flat (from year-earlier) Q1, but full year 2014 is expected between $7.8 and $8.2 million. Non-GAAP EPS is expected between $3.25 and $3.60.

The growth is based on new product ramps and expected approvals. Mylan sells generic drugs, so it has a large base of offerings and adds many new therapies each year. The FDA has a bit of a backlog, but that has been taken into account in the guidance. There is likely upside to the guidance if all the new therapies are approved and introduced in a timely fashion.

As of 11:37 A.M. Pacific Time, Mylan is trading at $56.47, up $5.05 or 9.8%.

In the long run Mylan looks even better. Management believes non-GAAP EPS can hit $6 per share in 2018. If you can wait that the long the stock should be worth roughly $120 per share.

Tuesday, January 14, 2014

Celgene in 2017: $375 per share or more


Recently Goldman Sachs panned Celgene (CELG), downgrading the company to a "Sell." A few days later Nomura started Celgene as a "Buy". Celgene is one of my key long-term investments and has provided a lot of alpha for my portfolio. Lately it (or at least the stock price) has been outrunning my cautiously optimistic projections.  Should I sell, take profits, and reinvest when or if the price normalizes? Or is there a factual basis to revise my past calculations upward?

I last wrote about Celgene on July 30, 2013 in "Celgene Up Over 100% In A Year: Still A Buy?" I concluded then that even at over $140 per share a prudent investor would buy Celgene, based on my estimated minimum $200 per share price in 2017. But Celgene closed on Friday, January 10, 2013 at $169.81. Its 52 week high was $173.80. Even if it were to reach $200 in 2013, that would only require a $10 advance per year, or about 6%. That is not what I consider good alpha, though it still beats bonds.

As always, the truth resides in the fundamentals. At pharmaceutical companies fundamentals have their foundation in future sales of currently approved therapies and in pipelines. There were quite a few developments at Celgene in the second half of 2013 that effect these foundations. The pace of sales of its key current drug, Revlimid for multiple myeloma (MM), increased, while new data indicating a label expansion to newly diagnosed  MM is possible was positive. Abraxane was approved for pancreatic cancer, in addition to its earlier approval for breast cancer. Pomalyst/Imnovid was approved for MM and sales have ramped quicker than expected.

Apremilast turned in good data for psoriasis and related diseases in 2013. Its market name will be Otezla, and FDA approval is expected this year (of course there is no guarantee of that). Celgene expects Otezla sales to reach $1.5 billion, or perhaps as high as $2 billion, in 2017.

On January 13 Celgene released preliminary Q4 and full 2014 results, as well as 2014, 2015 and 2017 estimates. Short term investors will want to focus on the Q4 results and 2014 estimates. Short-term, I'll just note that Celgene has a high P/E (price to earnings) ratio; maintaining it requires investor confidence in a high rate of profit growth.

As a long-term investor my interest is in where Celgene stock could reasonably be at the end of 2017. The easy answer comes from not doubting any of the parts, but accepting Celgene's 2017 estimate. Celgene projects revenues of $11.5 to $12.5 billion in 2017, up from $6.5 billion in 2013. Given operating margin estimates, the resulting non-GAAP EPS is expected to be in the vicinity of $15.00, compared to near $6.00 in 2013.

One way to project forward is to take the gain in EPS and multiply that by the current stock price. $15.00 / $6.00 = 2.50. Using a stock price rounded to $170, that would give us $425 per share. The percentage rate of increase, non-compounding, to reach that would be 37.5%. If this were guaranteed, no investor would want to miss out on that kind of growth rate.

Being more conservative, I would guess that today's high P/E will have normalized somewhat by 2017. Maybe the pipeline and projected earning s increases will have decelerated by then. I'll use a PE of 25, which still assumes Celgene is growing at a fair clip in 2017. 25 x $15.00 = $375 per share. That gives a non-compounding growth in the stock price of 30% per year. Still something not to be passed up.

In looking out four years to 2017 we need to recognize that a lot of things could go wrong. Private insurers or government health plans (particularly outside the U.S.) could demand lower prices for therapies. A new competing therapy could come to market and take market share. An unexpected adverse reaction to a therapy could be discovered. Or operating costs might exceed estimates, lowering profits.

Being aware of all that, I also note that the picture could be even rosier than outlined by Celgene management. As far as I can tell, the 2017 figures do not include any revenues from the pipeline except for Otezla. It is worth taking a brief look at the pipeline (excluding expanding current therapies to new targets):
For lymphomas, there is the Btk inhibitor CC-292 in Phase I; it is also in Phase I trials for Chronic Lymphocytic Leukemia. Sotatercept is in Phase 2 trials for a variety of anemias. CC-122, CC-115, CC-122 and CC-486 are in Phase I trials for solid tumors. In the anti-inflammatory segment we have CC-11050 in Phase II for cutaneous lupus erythematosus and CC-220 for undisclosed targets in Phase I. For Crohn's disease Celgene has PDA-001 in Phase I. Last on my list, a cellular therapy for organ transplants, UCB + HPDSC is in Phase I.

So, at least balancing the possibility that Celgene will not hit its 2017 estimates, there is the possibility that one or more of these earlier-stage therapies will gain FDA approval and begin generating significant revenue, or at least foreseeable revenue, before the end of 2017.  Celgene also can buy or generate (internally or with partners) new potential therapies, or advance preclinical candidates to human trials, but I don't see those as generating income by 2017.

In conclusion, while there are risks involved, I see no reason I should not hold my Celgene stock until 2017, when my expected value would be $375 per share. I also see no impediment to long term investors buying at current prices. Of course, if Goldman's negative view of biotechnology, or of the market in general prevails, there could be better price entry points than the $160 to $170 price range we have mostly been in lately.

I would like to buy more Celgene, especially since I sold some shares in October (at $156.74) in order to keep CELG within my portfolio limits for holding any single stock. I bought my CELG mostly in 2007 and 2008. I have to weigh that possible action against the benefits of diversifying into other biotech stocks and other classes of stocks. I hope sharing my thoughts will help other long-term investors with their thinking about Celgene. As to short-termers, what they do seldom affects the long run. But I thank them for providing liquidity and an air of excitement to investing in stocks.

Thursday, January 9, 2014

Dot Hill Ups Guidance; My Good Call

Dot Hill (HILL) updated its Q4 2013 guidance today. I just want to point out that this made my prediction in

Dot Hill Likely To Reach $4 Per Share In 2014 of August 8, 2013, come true following the press release.

It also means I am not so much out on a limb with my recent article:

Nearly Quadrupling In 2013, Dot Hill Still Has 2X Potential In 2014 [December 29, 2013]

Most likely Dot Hill management will give 2014 guidance when they report Q4 earnings in February or Early March. My EPS estimate for 2014 may prove to be rosier than HILL's, but I appear to have the direction right.

Here is the press release link: Dot Hill Revised Q4 Guidance

Here's my favorite sentence from that release: "More importantly, during 2013, we announced many new flagship vertical markets' customers that we expect will be the foundation for continued growth into 2014 in Big Data, Oil and Gas and in Media and Entertainment." That is from Dana Kammersgard, CEO.

As I write HILL is up $0.57 or % to $4.04, after being considerably higher earlier in the day. Some day traders made a killing, some must have taken a bath, but I am a long term investor. With today's price rise HILL became the largest component of my portfolio. I look forward to the day when HILL can start paying a cash dividend, but that is not likely to be in 2014.

If you really want to understand Dot Hill, you may want to read some of my Notes on Dot Hill analyst calls.

Keep diversified!

Saturday, May 25, 2013

Marvell Technology (MRVL) Q1 results & conference notes

Marvell Technology Group (MRVL) reported results on Thursday, May 23 that were at the high end of prior guidance. You can see my notes on the analyst conference at Marvell analyst conference, fiscal Q1 2014.

The most significant point is that new products that have been a couple of years in development should start ramping revenues in the second half. While no specific guidance was given for Q3 or Q4, the guidance for Q2 was revenue between $770 million and $800 million, which would be a significant sequential increase.

I own stock in Marvell.

Tuesday, April 30, 2013

Biogen Idec Too High Too Fast?

Biogen Idec (BIIB) is now off its 52-week high of $226.18 (reached earlier today) but up from a 52 week low of $126.39 (of June 4, 2012). At $218.84 it has risen 73% off the low.

I began following BIIB in the first quarter of 2006, but did not acquire stock until February 2008, when I picked it up at $61.57 per share. In the short run I overpaid, but I picked up more later that year at $46.97. I person with perfect timing could have picked up shares at $40.27 on November 28, 2008. Biogen then  rose to $67.05 by the end of 2010, and looks like it invented an anti-gravity machine this January.

Biogen did so well that it became too large a percentage of my portfolio (according to my portfolio rules) so I sold half of my position on May 16, 2012 for $137.19. Now of course I wish I had violated my portfolio rules and kept the stock longer, but I had other situations where those same rules kept me out of major trouble (they were the main reason I sold most of my Dendreon stake before the price collapsed).

Even though my remaining Biogen stake is well within my portfolio rules I have to ask: is BIIB overpriced? Should I sell it and look for a better value proposition?

There were reasons Biogen was priced where it was in 2008 through 2010, the big one being a disease called PML (progressive multifocal leukoencephalopathy) caused by the JVC virus. Biogen's specialty is multiple sclerosis MS therapies. Its Avonex was the most prescribed MS therapy, but the new wonder drug was supposed to be Tysabri. MS is an autoimmune disease; MS therapies work by selectively suppressing the immune system. Turned out, the JVC virus lurks in the brains of about 1/2 the population, generally doing no harm except when the immune system collapses, when it causes PML, and often results in death.

Tysabri use led to some PML cases, and in a few instances to death. Not knowing what the rate was, nor what treatment could be given for PML, the FDA revoked Tysabri's marketing license. The immediate solution turned out to be to monitor for PML and stop giving Tysabri if there were symptoms. The FDA re-approved Tysabri provided a monitoring program was in place. While Tysabri was so effective that sales ramped back up substantially, naturally there was concern by doctors, patients, and investors that we might see more PML deaths and a permanent ban on Tysabri.

Nevertheless in Q1 2008 Tysabri sales were $115 million, total Biogen revenue was $942 million, and GAAP EPS was $0.54. It being the recession, investors were risk-adverse, and it seemed no amount of good news on Tysabri, revenue, or profit could do much for the stock until late 2010.

So much of the run up in the price was just investors catching up to the new reality: a highly-profitable biotechnology company with a strong pipeline of potential future blockbusters. But in the same way investors lagged reality before 2011, perhaps so many momentum players have jumped on the BIIB bandwagon that the stock has gotten ahead of its fair valuation.

By the beginning of 2013 we had pre-screening for JVC and better treatments for PML, reducing the risk of PML mortality to statistically close to zero. We have substantial Fampyra revenues, though that therapy had also had its issues.

Plegridy (peginterferon beta-1a) for relapsing MS pivotal Phase III data has met all primary and secondary endpoints after 1 year cutoff of a two-year study. Biogen expects to file with FDA and EMA (Europe) by mid-2013

Daclizumab-HYP Phase III data readout expected in 2014. It is also for relapsing forms of MS.

Biogen also filed for approval with FDA for Hemophilia Factor 8 for A and 9 for B, based on significant Phase III trial results.

A number of other therapies are in Phase I, II, or III trials. See the Biogen-Idec product pipeline for more details.

So we can figure that the most likely scenario is that Biogen Idec will see substantial revenue and profit growth over the next few years and new therapies come to market. It is unlikely that everything in the pipeline will get good results and FDA approval, but Biogen has a lot of shots on goal.

You can build spreadsheets (and I have, and sell-side analysts certainly do) guessing at revenue and profits from future therapies based on patient populations, competing therapies, and guesses about pricing. But experienced pharmacology and biotechnology investors know that promising therapies often fail, and unexpected side effects can show up even after FDA approval. Picking winners of competitive races is also more guesswork than science.

So a good hard look at the latest quarter should keep us anchored in reality, and then some P/E ratio points can be added to reflect optimism about profit growth in the next few years; add as many points as you are comfortable with.

Biogen reported on the first quarter of 2013 last Thursday. Revenue of $1.415 billion was up 9.5% from Q1 2012, which is quite good and means a fair P/E ratio should be above the market average. GAAP EPS was $1.79, up 43% y/y; now that should be worth some a P/E ratio well above market. Ballpark it at 30 to 1.

Guidance is for 2013 GAAP EPS of $6.69 to $6.90. Given that non-GAAP guidance is $7.80 to $7.90, let's use $7.00 and multiply by 30. That gives us $210 per share, not much off today's auction price.

So my ballpark estimation is that even at this price BIIB is still a good value. Included in the price are estimated 2013 profits. The pipeline of new drugs revenue and profits won't kick in substantially until 2014. I would expect BIIB to end 2014 in a higher price band, depending on the details of new product ramps.

I am inclined to hold my BIIB and, if I need to sell stock because I spot another opportunity as good as Biogen was in 2008, I could probably find something else to sell. Most likely I will leave BIIB off the leash until it again becomes a risk management problem from being too large a percentage of my portfolio. If I am wrong and it falls in the short run, or becomes a smaller percentage of my portfolio again because something else runs up, I might even buy more.

Keep diversified!

Disclaimer: I own share of BIIB and reserve the right to sell them or buy more at any time, even though I currently have no plans to change my position.

See also:

My Biogen Idec main analyst conferences page.
My BIIB Q1 2013 conference notes
www.biogenidec.com

Monday, April 22, 2013

Applied Materials, Process Nodes, and Future Profits

Applied Materials (AMAT) makes capital equipment for semiconductor chip manufacturing. Demand in that sector has not been robust these last couple of years, although it has come off the bottom that lagged after the recession. This article will look at AMAT as a long-term investment, not a short term trade. Given that, the first thing to note is that it pays a dividend, which is currently $0.10 per quarter, or 3.1% per year at the current $13.06 stock price.

I believe the largest factor determining future AMAT revenue and profit will be the ongoing trend towards new, small process nodes (indicated by the size of the lines used to put transistors in chips. 32 nanometer is older than 28 nm.) But let's start with where we are now.

AMAT last reported on February 13 for the first fiscal fiscal quarter of 2013, which ended January 28, 2013. Against an overall global semiconductor capital equipment spending drop of 16% in 2012, AMAT reported revenues of $1.57 billion, down 5% sequentially from $1.65 billion and down 28% from $2.19 billion in the year-earlier quarter. That is discouraging, for certain.

Applied's core semiconductor equipment business saw a Q1 y/y decline to $969 million from $1.34 billion, a decline of 28%. Its display screen segment did better, but the solar segment did worse. Display revenue dropped 17% y/y to $87 million from $104 million, which was already low by historic standards. Solar revenue dropped 77% y/y to $47 million from $206 million. There is a glut of solar supply in the market, so no turn around is expected until at least 2015. Display may see some rebound in 2013 as screen sizes start to increase in developing markets and new screen technologies are adapted.

The bulk of Applied's revenue and profit comes from the semiconductor segment. It is well known that demand for PCs has been down, and it is hard to predict where the bottom may lay. Demand for tablets and smartphones has been increasing. Overall demand is dampened because smartphones simply contain far less silicon than PC's do. They have weaker processing chips and far less memory.

Does that mean Applied and other semiconductor equipment manufacturers should be written off as dinosaurs? I think not. I think overall computational demand will continue to increase rapidly for at least the next two decades. To cram more computation into portable devices (and the computers in the cloud that serve those devices) the industry will continue to move to smaller process nodes.

Right now demand is still high at the 28 nm node. Most chips, which work in legacy, non-mobile applications, are still made at much older nodes. For high-end graphics chips from AMD and NVIDIA, 28 nm is the cutting edge. Intel is already manufacturing its newest CPUs at 20 nm, and new memory-chip production at Samsung is just started at 10 nm. Memory process nodes typically can be smaller than computing process nodes. The most advanced ARM-based chips were recently taped out at 16 nm at TSMC.

Smaller (newer) process nodes mean that more capability can be built into mobile devices (and also non-mobile devices). Transitions to 14 nm and 20 nm are almost entirely ahead of the industry. To some extent moving to these nodes may open up capacity at 28 nm, but there is a lot of technology out there that has yet to migrate to 28 nm.

The other factor is overall demand, and that depends on the global economy and the frequency of consumer upgrades. There is a lot of old equipment out there, as seen by the high percentage of PCs still running Windows XP. With the exception on Intel, Samsung, IBM, and a few others, most chip makers are now really chip designers who send their designs to foundries like TSMC and Globalfoundries for actual production. These foundries don't want to have capital equipment sitting idle, but neither do they want to lose business because of insufficient capacity.

Generally capacity has been lean since the recession, which is one reason why there has been a shortage of 28 nm capacity. The other reason 28 nm has been tight is it was harder to get it working with good yields than had been expected There is quite a bit of impatience right now among the more cutting-edge designers because of a lack of sub-28 nm capacity.

Anything under 28 nm is far more expensive to make than 28 nm. Only Intel and Samsung have had the vast capital resources to simply move to the lower nodes without concern about how much demand would be there at startup. Even Intel announced it was cutting back capital equipment spending by $1 billion in 2013 due to lower demand projections.

But what is bad for foundries is good for AMAT and other equipment manufacturers: future nodes will require far more spending on capital equipment. One reason is that some 20 nm chips will have a 3-D structure. This means a move away from lithography defined shrinking to process-defined, where with precision engineering AMAT claims a considerable advantage.

In addition to reporting revenue, AMAT reports orders for each quarter. The good news for Q1 was that orders of $2.11 billion were well above revenue and up 31% from orders in Q4, as well as up 5% y/y.

Guidance is for Q2 fiscal 2013 revenue to be up 15 to 25% sequentially. Non-GAAP EPS is expected between $0.09 and $0.15.

While Applied Materials has substantial competition in each of the types of tools that are needed for semiconductor manufacturing, it is second in overall sales revenue only to ASML in an industry where scale matters. ASML is not much bigger: it had sales of $7.9 billion in 2011, AMAT had $7.4 billion. Another American competitor is KLA-Tencor, which had $3.1 billion in sales, placing it fourth globally.

On the whole, I think it is likely that 2013 will be a year of improvement for AMAT, and with major gearing up for 20 nm in 2014, that will be a very good year. How much improvement depends on the degree of strengthening global demand for semiconductor chips.

Disclaimer: I am a long-term investor in AMAT. I also am long AMD, but do not own any other company mentioned in this article. I will not buy or sell AMAT stock for one week following this article's publication date.

See also:

My main AMAT analyst conferences page.

My Q1 2013 AMAT analyst conference notes

www.appliedmaterials.com

Tuesday, March 12, 2013

Akamai (AKAM) 2013 Outlook Bright

"Some experts mutter dark warnings about the Spamularity: the global Chaos
that will ensue once the first distributed spamming engine achieves
human-equivalent sentience."—Rule 34 by Charles Stross

Akamai was one of the survivors of the original Internet bubble, and for years was characterized by the volatility of its stock price. Specializing in Internet content acceleration, over the years it became the IBM of this field. Money was being made, and so there was intense competition, and shorts sometimes heralded the fall of Akamai. AKAM always stayed a footstep or two in front of its competition. More importantly, it branched out.

Content acceleration has always been important to AKAM, but for years it has been adding other services to its repertoire. Content acceleration is a volume-driven, price sensitive business, with a record of constant declining y/y prices, much like mass-market semiconductors. Akamai's new services, notably Internet security, are also competitive, but have offered much better profit margins that should hold up at least in the near term.

So why is AKAM priced today around $34.71, well off its 52 week high of $42.52 on January 1, if well above its 52 week low of $24.90 on June 5, 2012? In the past AKAM was a playground for momentum players; it was a relatively small company, and you might see PE ratios swing wildly between say 20 and 60. Lately the stock is behaving more like IBM, more stable, with a much smaller but still impressive market cap of $6.2 billion. At the price quoted above the PE is 31.1 trailing, which is higher than most tech stocks at the moment, but easily justified by a history of growth and the outlook for 2013.

For the latest reported quarter, Q4 2012 ending December 31, Revenue was $377.9 million, up 9% sequentially from $345.3 million and up 17% from $323.7 million in the year-earlier quarter. GAAP net income was $68.3 million, up 42% sequentially from $48.2 million and up 14% from $60.1 million year-earlier.

Akamai just re-issued guidance for Q1, which this late in the quarter should be pretty reliable. Revenue is expected between $352 and $362 million. On a sequential basis that may seem disappointing, but keep in mind that Akamai gets a yearly Q4 bump from the increase in e-commerce in the quarter. Compared to year-earlier revenue of $319.4 million, we get an annual growth rate of 10% at the low end and 13% at the high end.

The dynamics of the business appear to be favoring Akamai. Cloud infrastructure revenue, rather than content acceleration, was 60% of total revenue in Q4. The security component of that was up 5x from the previous year. A major rival, AT&T, has thrown in the towel and is becoming a reseller of Akamai services, which should add substantially to revenue in the second half.

Even the underlying trend for the content acceleration business shows no sign of ebbing. Akamai was founded in 1998. It is just 15 years old. Humans in that age bracket are in an always-connected culture dominated by video and cloud services that often require data packets to be sent from a vast assortment of geographically diverse server farms. The amount of data being served will continue to increase, and Akamai essentially runs a private toll road system within the Internet for those who want the fast service that is essential to capturing customers and converting views to sales.

I like Akamai at this price. I expect it will blow through its current 52-week high some time this year as revenue and profits from the relatively new cloud security business and other new value-added cloud services ramp.

Disclaimer: I am long Akamai. I will not trade the stock for 1 week following this post.

See also: Akamai Investor Relations
My main AKAMAI analyst conferences page.
My conference notes for the Akamai Q4 2012 analyst conference

Friday, February 8, 2013

Microchip Record Revenue should be Topped in March Quarter

Microchip (MCHP) yesterday reported December quarter (fiscal Q3 2013) results slightly above analysts' consensus and in line with the mid-range of its prior guidance. Normally the March quarter is seasonally down from the December quarter, but in its guidance Microchip predicted sequential revenue growth. As a result in Microchip, which closed at $33.94 before reporting results, has climbed to $36.60 so far today. Microchip's current 52 week low is $28.92, and its 52 week high is $37.50.

Part of the strong revenue results resulted from the acquisition of SMSC. The same acquisition led to charges that hit GAAP profits pretty hard, but excluding those items non-GAAP profits and free cash flow were strong.

Microchip's model involves a focus on microcontrollers and related analog functions (touch screen control, wireless, and power management), with a wide variety of parts available to meet specific customer needs. Record revenue in quarter reflected a broad-based uptick in demand across industries and geographies. Revenues were $416.0 million, up 9% sequentially from $382.3 million and up 26% from $329.2 million in the year-earlier quarter.

Guidance to March quarter revenue of between $420.2 and $432.7 million, despite the usual hit from Chinese Lunar New Year, is based both on a continuation of the underlying trend and on design wins. Quite a number of design wins were announced in 2012; these are now resulting in orders that should ramp through 2013.

Microsoft has been a reliable dividend payer. At today's price the dividend yield is 4.15%.

Normally I use GAAP profits as a baseline, but non-GAAP numbers can be more informative for the long run when GAAP is affected by acquisition charges, as was the case in calendar Q4.

GAAP net income was $10.2 million, up sequentially from negative $21.2 million and down 87% from $77.5 million year-earlier. GAAP EPS (earnings per share) were $0.05, up sequentially from negative $0.11, but down 87% from $0.38 year-earlier.

In contrast non-GAAP net income was $84.5 million, EPS was $0.41, which is an improvement on, but consistent with, prior quarters. Free cash flow was $123.2 million, of which Microchip paid $68.7 million in dividends.

Microchip is still recovering from the cautious buying and weak end demand earlier this year. Inventories were reduced in Q4 and will continue to be reduced through June. On the customer side inventories are believed to be extremely lean, which could also result in increased buying if final demand shows signs of improving with the global economy.

I first invested in Microchip in 2006, based largely on my familiarity with their microcontroller products. It has been a reliable source of dividends and appears to have a first-class management team. I would recommend the stock to almost any class of investor.

Disclaimer: I own Microchip stock. I will not trade MCHP for at least 1 week after this story is published.

See also:

www.microchip.com
My main Microchip analyst conferences page.
My Microchip February 2013 analyst call notes

Saturday, January 26, 2013

Celgene (CELG) 2017 Guidance: Two Times 2013 Revenue

Celgene, based in Summit, New Jersey, is a biotechnology and pharmaceutical company best known for its Revlimid therapy for multiple myeloma (MM). At its analyst call to discuss fourth quarter 2012 results, CEO Robert Hugin projected that revenue would hit $6 billion in 2013 and grow to $12 billion by 2017. He believed profits (non-GAAP EPS, earnings per share) would grow even faster, at an average of 25% per year through 2017.

Last night I heard a high-level twit on NPR's Marketplace say that he would not buy stocks at this level because they have gone up so much in the last year, and in over the years since the 2008 collapse. Would he say the same about Celgene in particular?

Celgene's stock price took a hit during and following the 2008 selloff, reaching a low of $38.33 in 2009. Here are end-of year closing prices since then:

2009: $55.68
2010: $59.43
2011: $67.60
2012: $78.47

A naive investor might think that after a run up over four years buying at $78.47 would be a very risky thing to do. But in less than a month Celgene jumped to Friday's closing price of $99.76.

This is not idle speculation. Celgene stock has risen because revenue and profits have risen. It will rise further if revenue and profits continue to rise. So the question an investor should be asking is not what the price history is, but what reasonable projections can be made about profits.

The rise of Celgene to a top-level company has been driven largely by Revlimid sales, which accounted for $1.0 billion in revenue in the fourth quarter, or 70% of overall revenue of $1.42 billion. That might indicate a risky concentration in a single drug. Drugs typically pick up competitors over time, and eventually go generic. Should we discount the value of profits coming from Revlimid?

Revlimid's original approval was not for MM, but for MDS, myelodsplastic syndromes, and it is still used for that indication. Revlimid received FDA approval for MM in 2006, so it is a relatively new drug. Revlimid revenue is projected to continue to mount for three reasons. Revlimid has not yet fully penetrated the global market for its current label, which is for second line therapy, in other words for "patients who have received at least one prior therapy." There are still nations in the process of approving the therapy, of approving reimbursement, or of ramping commercially. A bigger factor is clinical trial data suggesting that Revlimid should have its label expanded to include first line therapy, which would give it a bigger share of the MM market. The length of therapy has been increasing and should bet a good bump from the shift to first line. Longer therapy means more revenue per patient.

Yet most of the projected expansion of Celgene revenue does not come from Revlimid. Revenue in Q4 from Vidaza was $216 million; from Abraxane was $106 million; and from Thalomid was $73 million. Except for Thalomid, all these therapies should see revenue growth. Abraxane, in particular, has clinical data showing it is effective for two hard-to-treat cancers, pancreatic and melanoma, in addition to its current label for breast cancer and its recent FDA approval for non-small cell lung cancer. FDA approvals are likely some time in 2013.

Apremilast for psoriasis and psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis will likely be a blockbuster, with good clinical data in psoriatic arthritis likely leading to FDA approval this year. and Istodax has already received FDA approval and will generate revenue in 2013. Pomalidomide is in a Phase III trial for myelofibrosis and reported good results for MM. The FDA should complete its review by February 10, 2013.

Beyond these leaders, Celgene has a potential product pipeline so deep I'll just suggest you click on the link and gape at it.

Of course, the future could hold twists we cannot foresee. Celgene's Hugin is not guaranteeing a certain level of profit for 2017, or any particular stock price.

I find Celgene's 2017 revenue and earnings guidance quite credible. Given that, the price per share in 2017 should be in the $200 to $230 dollar range, given a typical stock market with typical price-to-earnings ratios. Also assuming that in 2017 it looks like there is more growth ahead.

Celgene is in the Nasdaq 100 and S&P 500, so several index funds include it. It is in most biotechnology funds as well, for instance the Nasdaq Biotechnology Index (IBB).

Remember, no matter how good you think a single company's future look, diversified portfolios can provide much more safety while retaining a high degree of potential growth. Keep diversified!

See also:
www.celgene.com
My Celgene main analyst conferences page.
My Celgene Q4 2012 conference notes

Disclaimer: I have owned Celgene stock since 2007. I will not trade in CELG for at least 3 days from this article's publication date.

Wednesday, January 23, 2013

AMD sure of turnaround in 2013

AMD hit revenue guidance for the final quarter of 2012, but the numbers were still dismal. Revenue was $1.16 billion, down 9% sequentially from $1.27 billion, and down 32% from $1.69 in the year-earlier quarter. Guidance is for Q1 2013 revenue to be down around another 9%. Net income was $473 million in the red on a GAAP basis, and even on a non-GAAP basis was $102 million short of break-even.

Despite that AMD CEO Rory Read were surprisingly upbeat about 2013, predicting the a return to profitability in the second half. Of course we've heard that kind of optimism from AMD before, only to be let down. Are AMD's claims of a turn-around ahead credible?

AMD is currently known for making CPUs that compete with Intel's for personal computers (notebooks and desktops) and servers. In addition AMD makes stand alone graphics chips (GPUs), competing mainly with NVIDIA. AMD has not done well in the server space these last five years, and the PC space has started to shrink, in part because tablets and smartphones have become more popular and mostly use ARM based CPUs, rather than the more capable and power-hungry x86 coded chips made by AMD and Intel.

In 2012, in an effort led by the remarkable vice president of global business units Lisa Su, AMD started to re-target its intellectual property development towards growth sectors. The acquisition of SeaMicro acted as an entry to the dense server space, where AMD's graphics expertise could eventually help with highly-parallel computations, and Opteron technology is a better fit than Intel's server chip designs. In addition, AMD has announced it will use ARM technology when appropriate in this field. Although the complete new system will not be available for some time, Rory reported that Q4 SeaMicro revenue grew.

A second major line of attack is embedded SoC chips. This is a bit of a vague term; as used by AMD, it seems to amount to the non-PC sector. SoC, System on Chip, typically means that the chip is not a stand-alone CPU. In reality, even what we now call CPUs are not stand-alone CPUs: AMD has been a leader in moving critical components that "glue" the CPU to the rest of the system, like memory controllers, onto a single chip. Embedded SoC in this case means customized for a particular application. Rory indicated AMD would be looking only at relatively high-volume applications as margins have been too low in some low-volume systems. Examples of possible embedded AMD chip use would be for advertising displays, casino machines, industrial and medical use.

AMD does not currently break out embedded revenue, but the goal is to raise it to 20% of revenue by the end of the year. No word on whether that is 20% extra revenue or 20% replacement of eroding PC revenue, and Rory made it clear no details would be announced until the OEMs are ready to announce them.

The PC business, of course, is still critical, as is the entry into tablet computing. Rory made a point that AMD engineers are executing well, making their timeline, and in one crucial area are about 6 months ahead of Intel. Along those lines, AMD has demonstrated working Temash and Kabini silicon. These APUs will be quad core SoCs for the tablet and mobile markets. They also already introduced the new Richland A series APU, upgrading a sweet spot in their line.

This morning as I write AMD has popped from its pre-conference and results close of $2.45 up 9% to $2.67. Obviously no one knows if AMD will be able to execute its plan or if, once products are available, they will sell well enough to bring AMD back to profitability. It has the look and feel of a good plan and a big turnaround to me, but I have been wrong about AMD in the past, and the sands of silicon are shifting rapidly and unpredictably. Before getting bullish on AMD, I'd like to see the 2013 products, the revenue, and the profits.

Disclaimer: I have long been long AMD and will not trade the stock for 3 days after the publication of this report.

William P. Meyers

See also:

www.amd.com

My main AMD analyst conferences page.

My AMD Q4 2012 analyst conference notes

Monday, October 29, 2012

Marvell (MRVL) Wins Microsoft Surface RT Wi-Fi slot

Marvell Technology Group (MRVL) won a slot in the Microsoft Surface tablet computer. According to Anandtech (Inside Microsoft's Surface RT Tablet, October 16, 2012), the WiFi chip on the tablet is Marvell's. NVIDIA won the main prize with its Tegra 3 ARM-based processing chip. Atmel also had chips in the design.

We don't know how many of the WiFi chips Marvell shipped to Microsoft in the summer quarter (Marvell's fiscal Q3 2013 ending October 27, 2012), but it was not enough to balance the damage in the hard disk drive (HDD) controller chip business. Marvell dominates HDD controller chips, but the problem is that the largest single use of HDDs in in PCs. It was a terrible quarter for PC sales, and little HDD makers Seagate and Western Digital could do about it.

Marvell had guided revenues to $800 to $850 million. The update issued on October 18 put revenues at $765 to $785 million. At the midpoint there is a $25 million miss on the low end of prior guidance. Just about all of that came from the HDD segment. Marvell also makes chips for smartphones, for networking (ranging from WiFi to high-end datacenter Ethernet), for Google TV and similar appliances, and for video processing in HD TVs. It is moving into new areas like LED controllers.

The fourth quarter is a big question mark. A lot depends on the global outlooks of OEMs. If they are pessimistic they may further shrink inventories. If holiday sales go well, they may have to expand inventories, giving chip manufacturers like Marvell a boost.

While there is a lot of uncertainty about Q4 and about 2013, Marvell is well set to manage their way through it and eventually expand into new businesses, as they have in the past. Even at the current level of revenue Marvell is a cash cow. At the current stock price, $7.755 at the close Friday, you are buying $0.75 in trailing 12-month earnings and dividends of $3.1% per year, plus a cash balance of $2.13 billion, or $3.82 per share. In the latest quarter cash flow from operations was $0.34 per share. It looks to me like the market over-reacted to the revenue miss. At this price Marvell stock is well worth the risk, in my opinion. But then I started accumulating Marvell stock years ago.

Marvell is large enough and diverse enough that if only moderate numbers of Microsoft Surface tablets get sold, that probably won't have a significant impact on Marvell revenue or profit. Then again, the Windows Surface is a really hot device, and may sell in more than moderate numbers. It is on my wish list.

Disclaimer: I am long Marvell and Seagate. I will make no position changes in them for a week after this article is published. I do not have a position in Microsoft, Western Digital or NVIDIA and also will not initiate one for a week. Also, I occasionally do freelance work for Microsoft.

Monday, September 10, 2012

Microchip (MCHP) Pays Dividends

Microchip (MCHP) is one of the largest global manufacturers of microcontrollers, which are semiconductor chips incorporating computers and capabilities to receive data from sensors and send control signals to motors or other external parts. For investors the company is noted for its relatively high dividend and its ability to generate profits even during down cycles.

Today Microchip stock closed at $34.14, against a 52 week high of $38.87 and low of $30.07. At that price MCHP market capitalization is $6.6 billion, and the dividend yield is 4.05%.

Last week Steve Sanghi, the CEO, reported that after a sequentially up calendar Q1 and Q2, the business environment weakened towards the end of Q2, with Europe particularly slow. The situation has not improved, so Microchip is now guiding revenues to be about flat in Q3 compared to Q2, excluding the increased revenue from the recent SMSC acquisition. [Note calendar Q2 was fiscal Q1]

The SMSC acquisition closed August 2, at a value of $946 million. For fiscal 2012 SMSC had sales of $412 million and a non-GAAP operating margin of 12%. It will fit well with Microchip's product line, as SMSC is a specialist in smart mixed signal connectivity. Its revenues are 43% from microcontrollers and 57% analog products. These are used for automotive entertainment, wireless audio, and USB and Ethernet. Sanghi believes Microchip will be able to increase gross and operating margins of the acquisition closer to its own, high-marin model.

Microchip sells to a very diverse set of customers, including manufacturers of automobiles, household appliances, and medical and industrial equipment. Microchip also has an advanced touch screen set of solutions.

SMSC will provide a boost about 3 cents per share in the first partial quarter, then 6 to 7 cents in the first full quarter, fiscal Q3.

Steve pointed out that when Microchip bought SST it had not made a profit in five years, but has had good margins once integrated. He sees SMSC as a much less difficult business to integrate and profit from.

There is plenty of competition for microcontroller chips, but Microchip now has over 7% of the market, compared to under 2% in 1994, with the market share climb being pretty steady. In 2011 Microchip was the 4th largest player in the market after Renesas, Freescale, and TI. It is second in the 8-bit segment to Renesas, which moved ahead only when it absorbed NEC.

For fiscal Q2 2013, ending September 30, 2012, revenues are now expected between $12 and $430 million and non-GAAP EPS is expected between $0.50 and $0.52.

Given the high dividend, relatively low volatility of the stock price, and further opportunity for growth, Microchip remains a good core technology investment for long term investors. The main risk I see is macroeconomic.

Disclaimer: I have been long MCHP since 2006. I will not trade in the stock for at least one week from today.

See also: Microchip.com investors page; my Microchip fiscal Q1 call notes

Thursday, May 10, 2012

Dot Hill Reports Q1 Bounce

Dot Hill (HILL) is up today after reporting considerably better than expected Q1 revenues. Despite that, with expected revenues of over $200 million in 2012, its market capitalization is around $74 million. Is Dot Hill an overlooked prize, or is the market right about its value?

Dot hill manufactures data storage arrays for the low-end of the enterprise market, selling to OEMs that typically rebrand the devices. A few years ago Sun was their main customer, but Sun dropped them, leading to a crisis. HP is now their main customer. Management has been building an impressive list of other customers, reducing reliance on HP.

Revenues were $54.7 million, up 16% sequentially from $47.0 million and up 11% from $49.2 million in the year-earlier quarter. Usually Q1 sees a seasonal revenue drop from Q4, so these are impressive numbers. Part of the revenue, I am guessing in the range of about $4 to $5 million, came from orders from a particular customer that provides storage solutions to the telecom market. Management mentioned this could happen when they gave Q1 guidance in March, but they clearly hedged a bit.

The year over year comparison was the first good one turned in since NetApp was dropped as a client in 2010. I believe the prior negative year/year comparisons had been depressing the stock price, despite the compelling reasons for ditching NetApp.

GAAP net income was negative $1.8 million, up sequentially from negative $6.6 million, but worse than the negative $1.3 million of the year-earlier quarter. EPS was negative $0.03, up sequentially from negative $0.12, but down a penny from negative $0.02 year-earlier.

Even if we look at non-GAAP numbers, which drop out non-cash accounting charges, while HILL got into the black it was just barely: net income was $1.9 million. EPS was $0.03.

Guidance is that Q2 will be off Q1, with revenues between $48 and $52 million and non-GAAP EPS close enough to zero that it could be a plus or minus.

That is the past, what about the future? Technology companies can't dwell in the past, as RIMM, among so many others, have demonstrated. During the crisis (losing Sun during the recession) management started making smart moves about the future of the storage market. They are competing against giants, but they sometimes cooperate with giants like HP. Their storage products have actually received quite a bit of acclaim in the industry.

Some of the Q1 revenue growth came from new clients signed in 2011. Hill was able to win these customers because they produce very reliable storage technology at a reasonable cost and work hard for their clients. Autodesk and Concurrent Computer were cited as OEMs signed in 2011 that are seeing sales ramps. Official announcements of newer customers should be coming out as 2012 progresses.

Dot Hill has mainly served the entry-level enterprise storage market. Part of their success has been from adding higher level features to entry-level designs. New storage arrays that have mid-level enterprise features should be released in the second half of the year. OEMs are already excited about them, but a significant revenue ramp of the new products is probably a q4 and 2013 story.

On the whole Dot Hill management was upbeat, particularly about the second half of 2012. With the ramping of lines at newer OEM customers, Dot Hill should be able to enter an era of sustained profitability. Given that the company is debt free and holds $41 million in cash, there is a lot of upside potential if management can execute according to plan. In terms of share prices, I would be delighted, but not overly surprised, to see shares in the $3 to $5 range by mid 2013. I am also surprised, given their patent portfolio, that Dot Hill has not been a takeover target. Of course the usual risks apply, but I think all the risk is priced in at current levels.

Disclaimer: I am long Dot Hill. I won't make HILL trades for 1 week after publishing this article. I do not have positions in any of the other companies mentioned.

See also: www.dothill.com
My Q1 2012 Dot Hill analyst call notes

Friday, December 9, 2011

Applied Materials See Cycle Bottom

Applied Materials (AMAT), the semiconductor capital equipment maker, had a very difficult fourth quarter of fiscal 2011 ending October 30th. The stock is trading trading today around $11.20 per share, less than 8 times earnings and not that much above its 52 week low of $9.70 touched on October 4.

Yet revenue for the fiscal year set a record. Applied Materials and other semiconductor equipment makers tend to be very cyclical because demand for new equipment is only strong when semiconductor end use is ramping. It looked like calendar 2011 would continue to be part of a strong up cycle that started in 2010, but global economic turmoil and weak consumer electronics end demand has made chip makers and the foundries that serve fabless chip makers reluctant to increase capacity.

Sales continue because even during slow periods there are advantages to moving to new process technologies that put more transistors on any given area of chip surface. Applied Materials also derives considerable revenue from related services. Its services division contributed $629 million in revenue in the quarter.

Total Q4 revenue was $2.18 billion, down 22% sequentially from $2.79 billion and down 25% from $2.89 billion in the year-earlier quarter. GAAP net income was $456 million, down 4% sequentially from $476 million and down 3% from $468 million year-earlier. GAP EPS (earnings per share) were $0.34, down 6% sequentially from $0.36 and down 3% from $0.35 year-earlier.

Non-GAAP net income was $271 million, down sequentially from $467 million and also down from $476 million year-earlier. EPS $0.21. The vastly lower non-GAAP than GAAP earnings were mostly due to a $203 adjustment to the prior-year's income tax filings.

Despite the poor quarter, cash flow from operations was near $700, or about $425 million excluding the income tax refund. Cash and equivalents were over $7 billion.

The stock pays a dividend of $8 per quarter per share. Management reiterated that they are committed to increasing the dividend, but stock buy backs are the preferred method of returning profits to shareholders. The acquisition of Varian Semiconductor will put a temporary crimp in cash, but is a good long-term move.

Which brings us back to the question of where we are in the cycle. To some extent that depends on the global economy. It is also sector-specific, as capacity utilization and end demand growth differ for sectors like RAM, Flash memory, application-specific chips and display technology.

Applied Materials management has had decades of experience with these cycles. They expect the first half of their fiscal year 2012 to be difficult. In particular Q1 fiscal 2012 (ending January 30th) guidance was for revenues down sequentially another 5% to 15%. However, they believe they are already past the bottom of the order cycle. Because we are talking about capital equipment, when the order cycle starts trending upward it can be six months before actual revenues start trending back up.

Flash and mobile processor capacity utilization are already high, so any further increase in demand should generate equipment orders. However, RAM capacity is plentiful, so we probably won't see a big uptick in revenues until demand catches up to capacity in that segment, probably later in 2012.

Despite unevenness, we are still in a global economic ramp with billions of consumers set to acquire smartphones in the next 3 years (600 million in China alone). Everyone wants devices that do more with less power, and the only way to get that is with new semiconductor manufacturing capabilities. It does not matter who wins the smartphone race; everyone needs the kind of semiconductor manufacturing solutions Applied Materials provides.

For more details about Q4 results, including questions by analysts, see my Applied Materials Q4 2011 Analyst Call summary.

Disclaimer: I have a long position in Applied Materials (AMAT), with a long term view. I have no plans to change my position anytime soon.

See also: www.appliedmaterials.com

And keep diversified!

Tuesday, November 29, 2011

SGI Supercomputer Revenue Growth Continues

Looking for the technology company that reported calendar Q3 2011 revenue that was 58% higher than its Q3 of 2010? That would be Silicon Graphics International (SGI), manufacturer of high-performance technical computers (supercomputers) and high-efficiency server systems for datacenters and cloud computing.

GAAP revenues for fiscal Q1 2012 ending September 30, 2011 were $178.9 million, down 8% sequentially from $195.5 million, but up 58% from $112.9 million in the year-earlier quarter. GAAP net income was negative $2.7 million, improved sequentially from negative $12.1 million and improved from negative $11.2 million year-earlier. EPS (earnings per share) were negative $0.08, improved sequentially from negative $0.39, and also improved from negative $0.37 year-earlier.

While in the red on a GAAP basis, on a non-GAAP basis (mostly eliminating non-cash expenses like stock-based compensation) SGI managed a profit of $2.2 million, or $0.07 per share. SGI has gone through a period of investing to introduce new products, and also expanding its sales force. Profit margins could improve as further ramps in revenue should not require similar ramps in operating expenses.

While not giving guidance by quarter, for fiscal year 2012 (running to June 2012) revenue is expected between $740 and $780 million, up to 24% over fiscal 2011.GAAP EPS is estimated between $0.15 and $0.30. Non-GAAP EPS expected between $0.60 and $0.80.

How are they achieving such stellar growth while other computer makers are lagging? SGI specializes in expensive computers used for scientific research, as well as large systems for cloud computing and Web farms. These are all areas that continue to grow quickly. While there is competition from the likes of IBM, HP, Dell, and Cray, the newest systems introduced by SGI, notably Altix UV, are better at addressing the needs of their markets.

Nor is SGI resting on their laurels. They are introducing computers that run large scale systems running Windows SQL Server. They have improved their compatibility with Hadoop and Red Hat Enterprise Linux. They continue to be a major supplier for Amazon's cloud system. They also have started acquiring small companies that specialize in supercomputer application software. SGI expects that the ability to sell software as well as hardware will be a major advantage for verticals they service, with higher profit margins.

Finally, they ended the latest quarter with $115 million in cash with no debt. They did use $30 million of cash to build inventory in the quarter, but the systems built had been pre-ordered and should be shipping this quarter.

Because of the size of the systems involved, some quarter-to-quarter lumpiness is to be expected.

If you read what scientists are saying about Altix UV, you will realize why management has become very confident in SGI's future. On the analyst call they stated the next big SGI milestone will be $1 billion in annual revenue, which should bring between $1.75 and $2.00 non-GAAP EPS per share.

The recent growth has been in the face of a lot of uncertainty and a poor macroeconomy. Even so, if the doomsayers are right about global slowdown or meltdown scenarios in 2012, that could impact sales. I am more concerned about competition, but it does seem that for now SGI has found a niche where it can outcompete far larger companies.

For more details on calendar Q3 results, see my SGI Q1 fiscal 2012 analyst call summary.

Disclaimer: I am long SGI. I won't change my position for at least one week from today.

The usual risks apply, so keep diversified!

See also: www.sgi.com

Tuesday, May 10, 2011

Dot Hill Does Well By HP, Looks For More Partners

Dot Hill (Nasdaq: HILL), a data storage equipment manufacturer, had a very interesting analyst call reporting Q1 2011 results last Thursday. Until December NetApp had been Dot Hill's second largest customer. But profit margins for that particular relationship for Dot Hill were negative, and negotitions with NetApp were not fruitfull. So Dot Hill dropped NetApp.

The result was a pretty steep drop in revenue to $49.2 million, down 25% sequentially from $65.4 million in Q4, and down 18% from $60.0 million year-earlier. Q1 is typically the slowest quarter for Dot Hill. However, the profit hit was much less. GAAP Net income was negative $1.2 million, down sequentially from $0.3 million, but up from negative $6.4 million year-earlier. Non-GAAP net income was $0.1 million for EPS of $0.00, better than I expected.

HP, which buys storage arrays from Dot Hill and resells them under its own brand, was responsible for 76% of Hill's revenues in the quarter. Sales to HP grew 20% y/y. But Dot Hill knows the danger of manufacturing mainly for one customer. They used to make equipment almost exclusively for Sun Microsystems. That business disappeared several years ago.

In fact Hill already supplies to several other major players including Lenovo and Samsung. But in none of these cases is it the exclusive storage supplier. It also sells through a large number of smaller systems integrators, but in the quarter that only amounted to $1.2 million in revenue.

There are three relatively large opportunies for Dot Hill going forward, aside from just selling more through HP. LSI's storage division Engenio is being acquired by NetApp. Some of LSI's Engenio clients are NetApp competitors. Some have begun discussions with Hill about switching to Hill as a first or second source. The second opportunity is selling more software with its hardware solutions, which brings higher profit margins. The third is the industry is consolidating, and Hill is an attractive acquisition candidate, although no discussions have been announced.

Q2 is looking better than Q1, partly due to orders late in Q1 that did not ship until Q2. Revenues for Q2 are projected at between $49 and $53 million, with non-GAAP net income and EPS expected in the vicinity of break-even. When Hill takes on new major OEM clients it does customization for them, which incurs increased engineering costs.

It is notable that GAAP gross margins increased from 13.5% year-earlier to 24.6% in Q1. This was partly from dropping NetApp, partly from a higher-margin mix in the rest of the business, and partly from increasing sales of storage management software.

For a greater level of detail see my Dot Hill Q1 2011 analyst call summary.

I own Dot Hill stock.

See also www.dothill.com

Monday, September 27, 2010

AMD Lowers Guidance, But Stock Price Rises ... Why?

On September 23, 2010, AMD, a maker of CPUs for servers and personal computers, made a big downward correction in its guidance [See AMD Update Third Quarter Outlook]. Yet the stock shot up from a base of $6.40 the next day, and since has risen to $7.02 at the close today. In the past few years, AMD stock has not done well on good news, much less bad news. What is the difference now?

Some pundits think Oracle may buy AMD. That makes no sense to me. Oracle may be in the market for a chip stock, but the idea would be to improve their datacenter hardware offerings, which are now based largely on Sun's old proprietary processors. AMD would bring a lot of baggage with it. The only attractive things about AMD would be its engineering teams, which are first-class, and its low price. Its market capitalization was just $4.73 billion end of today, and its non-GAAP P/E is 4.56, about as low as you can get.

Buying AMD would put Oracle in the desktop and notebook chip business, which are low-margin businesses. Oracle hates low margin business. They shut down a good part of Sun when they acquired it because margins were not high enough to please them. What Oracle needs is a smaller chip company with skills storage and networking chips as well as data processing. Marvell would be a good acquisition, but I doubt very much Marvell Technology would allow itself to be acquired. An even smaller company would make more sense.

Back to AMD, it is most likely that the stock price bounce had to do with short covering. Lots of people like to short AMD, which is the perennial loser in its competition with Intel. Intel had lowered its third quarter guidance weeks ago. In general the PC industry was known to be having a relatively slow Q3. I think the problem for the shorts was that AMD's problems were already built into the stock price. In fact, the new guidance could have been a lot worse. Then there are the Fusion products that will begin shipping in Q4 and ramp in Q1 2011. No short wants to be around to see what happens then.

When AMD's price rose after the announcements, the shorts had nowhere to go. They had to cover their bad bets. Momentum players jumped in too, taking advantage of the distress of the shorts.

AMD's new guidance is revenue for Q3 "in the range of down one to four percent as compared to revenue of $1.65 billion for the quarter ended June 26, 2010." What investors should be looking for when AMD actually reports Q3 numbers on October 14 is margins. Did they at least get good prices for the CPUs and GPUs they sold? After that, look at guidance for the release of Fusion APUs. All evidence is that they will be widely and happily adopted by OEMs that want to offer consumers better graphics capabilities than Intel can provide.

See also: Can AMD Ignite Fusion? [June 7, 2010]

AMD Q3 guidance given at Q2 analyst conference [July 15, 2010]

Note: I currently own AMD and Marvell stock, but not Intel or Oracle.

Keep diversified!

Wednesday, March 31, 2010

Applied Materials (AMAT) Predicts Boom

Applied Materials makes the high technology capital equipment that fabricators use to make semiconductor chips, flat-pannel displays, and solar cells. In early 2009 this business was in stall mode. Revenues dropped to $1 billion for the quarter ending April 26, 2009 (AMAT's 2nd fiscal quarter).

In the first calendar quarter electronics sales were down, and chip manufacturers (fabs) thought had too much capacity. The only reason to buy equipment from Applied Materials was to stay on the upgrade path to new technologies, in particular smaller feature sizes.

Lately all the talk in the computer and electronics industry is about supply constraints. The fabs don't have enough capacity for the newest technologies that are in demand. Just for instance, neither AMD nor NVIDIA has been able to get the new high-end graphics chips in quantities desired.

So fabricators in Taiwan and elsewhere are trying to catch up to the curve. So much so that by the time Applied reported its latest earnings (on February 17 for the quarter ending January 31) revenues for the quarter were $1.85 billion, and net income was $82.8 million.

Guidance given on February 17 was for fiscal 2010 revenues to be up 50% over fiscal 2009 revenues.

But it gets better. Semiconductor chip manufacturers are ordering even more broadly just in the last few weeks. So yesterday Applied Materials increased its guidance. It expects fiscal 2010 revenues to be up over 60% from fiscal 2009. Leading the charge is the silicon manufacturing equipment division, which is expected to be up 120%. Lagging is the solar division, which is expected to be flat to slightly up.

Predicting the future is a dangerous business, but they it is a business I am in. Silicon is coming in quantity to nations like India, China, and Brazil in never-before seen quantities. Applied Materials is one of the few companies with the capital and expertise to keep pushing the limits on shrinking the size of the components on the chips. After minimal upgrading in 2008 and 2009, now through at least 2012 should be a major upgrade and expansion cycle for fabs.

There are small electronics and software companies that will grow faster over this period, but Applied Materials right now is both a value and a growth stock. It pays a dividend, 1.78% at this moment's stock price of $13.71. You will probably get most of your returns, however, out of stock appreciation.

I am a long-term AMAT investor.

Keep diverified!

See also my fiscal Q1 2010 Applied Materials analyst conference summary
And of course www.appliedmaterials.com

Friday, December 18, 2009

Oracle Analyst Conference report

Oracle (ORCL)

Note: I do not own any Oracle stock as of the date of this entry - William P. Meyers

conference date: December 17, 2009 @ 2:00 PM Pacific Time
for quarter ending: November 30, 2009 (2nd quarter fiscal 2010)

Overview: Strong sequential revenue growth with strong earnings.

Basic data (GAAP) :

Revenues were $5.86 billion, 16% sequentially from $5.05 billion and up 4% from $5.61 billion year-earlier.

Net income was $1.46 billion, up 30% sequentially from $1.12 billion and up 12% from $1.30 billion year-earlier.

EPS (earnings per share) were $0.29, up 32% sequentially from were $0.22 and up 16% from $0.25 year-earlier.

Guidance:

Excludes Sun acquisition.

Pipelines are strong, but assuming conservative close rates, 3rd quarter fiscal 2010. Revenue up 4 to 7% y/y at current exchange rates. Non-GAAP EPS $0.36 to $0.38 at current exchange rates. GAAP $0.26 to $0.28. 28% non-GAAP tax rate assumed.

Conference Highlights:

Exceeded high end of prior guidance. Software new license revenue was up 2% y/y to $1.7 billion (but down 5% in constant currency). Software updates and support revenue was up 14% y/y to $3.3 billion. GAAP operating margin was 37%, up from 35% year-earlier. This was the highest operating margin in Oracle history.

Non-GAAP results: operating income was $2.9 billion, up 9% y/y. Net income was $2.0 billion up 12% y/y. EPS were $0.39, up 15% y/y. Operating margin was 49%, up from 46.2% year-earlier.

Expects the Sun acquisition to clear with the European Commission in January.

Took market share from SAP "in every region around the world."

Exadata continues to be a "red-hot product."

Suns machines run Oracle databases "faster than IBM's fastest computer. We expect Sun to rapidly improve both its market share and margins once this merger closes." Oracle plans to avoid using Sun for the low-margin, high volume market. Will deliver "private cloud" complete solutions.

Stock holders of January 19, 2010 will receive a $0.05 per share dividend on February 9, 2010.

Cash, equivalents, and marketable securities balance ended at $20.78 billion. Debt in notes payable was $13.75 billion. 11.6 million shares of stock were repurchased for $253 million.

Operating expenses were $3.68 billion, composed of: Sales and Marketing $1.13 billion; product support expense $264 million; cost of services $832 million; research and development $708 million; general and administrative $183 million; amortization $436 million; acquisition related $10 million, and restructuring $114 million. Leaving operating income of $2.18 billion. Interest expense was $188 million. Non-operating income $33 million. Income tax provision $565 million.

Q&A:

Database business growth drivers? People had been putting off decisions, now some of that is starting to come back. 11g work with ISVs is kicking in as well.

Linearity? Typical linearity, not back-end loaded. But current quarter started off in better shape. Europe is lagging by about two quarters.

Guidance looks better than anticipated, does this mean there is a meaningful recovery in spending? We are seeing customers back buying, broadly. But it may be due to our strong products and sales teams. We also see the environment improving.

Are close rates improving? We did better than the close rates we expected. The economy is uneven, so we are continuing to use a very low close rates for guidance. Pipeline is very good, especially with Exadata.

Vertical standouts? Communications had a good quarter. Financial services pipeline is improving. Retail is coming back.

How big could Exadata business be? We think it will be huge, billions of dollars a year. How long it takes to get there remains to be seen. We want to group our industry standard components into machines like Exadata for transaction processing and data warehousing. Customers then don't have to do system integration. We want to apply the same strategy to operating systems, middleware, etc. We think that is what the computer business is going to look like for large customers going forward.

When we have acquired Sun all of you are going to have to redo all of your models.

Fusion products are SOA, so they can be bought individually and integrated easily.

List of my analyst conference summaries

My Oracle page

Thursday, February 5, 2009

Akamai Accelerates Delivery

Akamai (AKAK) investors were presently surprised by 4th quarter results released Wednesday. Starting after hours and continuing into Thursday new money poured into the stock, thrusting the price up. I own Akamai stock, but I looked at it for years before purchasing it. If you want some deep background on Akamai, go to my Akamai analyst conferences summaries page, which includes links to my articles on what Akamai does, how they do it, and how the profits are generated.

Fourth quarter 2008 results were not even spectacular by Akamai standards. Revenue was $212.6 million, up 8% sequentially from $197.3 million and up 16% from $183.2 million year-earlier. In past years revenues have grown faster. But this is in sharp contrast to 95% of the technology companies reports on the December quarter. During 2008 everyone said their company gave such great ROI (return on investment) that they would continue to see growth through a recession. Most did until Q2. Many did in Q3. But in Q4 almost every company saw a significant downturn. Even mighty Cisco reported falling revenues yesterday.

Akamai profits were good by any measure. Using the most conservative measure, GAAP net income was $40.5 million. But cash from operations was $92 million and the ending balance for cash and equivalents was $772 million.

Akamai has been periodically raided on rumors that competitors were going to steal its thunder. I don't want to underestimate the role of competition in technology. Akamai has a profitable model, and big companies with lagging sales will eye those profits and try to capture them, and startups will eye them. But so far Akamai has had a significant technological advantage over its competitors. Its systems work well. No competitor has introduced as capable of a system, so they have to compete on pricing. When they win an occasional deal, they often lose money or just break even. Meanwhile Akamai generates cash and uses that cash to see that its technology is the best. They have also added what Cisco likes to call "adjacent" technologies. Akamai calls them value-added technologies. When Akamai has a contract for its basic service - speeding up the delivery of Internet content - it is in a good position to offer higher margin, more specialized services as well.

Guidance is for flat to down revenues in the first quarter of 2009, but that is a typical seasonal effect from the post-holiday drop in e-commerce. The Web is still in explosive growth mode, with video downloads becoming prevalent, soaking up bandwidth. Akamai's fortunes are carried along by that explosive growth.

I think Cicso CEO John Chambers is right in believing that Internet traffic is not going to slow down; just the opposite. So ISPs and carriers are going to have no choice but to lay more wire and install higher capacity routers. They delayed doing that in the December quarter, they might delay capital expenditures in the March 2009 quarter, but they are just getting behind the curve and will have to make up for it at some point.

In the meantime Akamai is not dependent on major capital expenditures by its customers. There are a lot of customers, and Akamai services are a relatively small recurring part of their Web delivery budgets.

There have been times when, by my analysis, Akamai stock has been overpriced, but now is not one of those times, even with today's pop.

Don't forget the risk even for good companies, and

Keep diversified.

See also: www.akamai.com